Jatenergy provides update on Golden Koala production run

By Megan Graham. Published at Oct 1, 2018, in Juniors

China-Australia cross-border specialist in Fast Moving Consumer Goods (FMCG) exports, Jatenergy (ASX:JAT) has published an update on its website regarding its subsidiary Golden Koala.

The company advised that Golden Koala’s first container loads of the newly formulated, and freshly packaged milk powders were all ready to ship. The production run includes infant, follow-on and toddler formula as well as adult milk powder.

Its products, with English language packaging, are to be sold in Australia as well as via daigou and cross-border channels to Chinese customers.

Perhaps in response to these and other developments, JAT’s shares performed well on Friday, at one stage up as much as 10% to 4.5 cents.

Last month, the company announced that Green Forest, a 50% owned subsidiary of Jatenergy (ASX:JAT), had secured a distribution deal to supply China National Pharmaceutical Group Corporation (Sinopharm) with its Australian product range.

Sinopharm is of the world’s biggest pharmaceutical companies, with over 5000 stores across China. It ranks 194th in Fortune’s 2018 Global 500 and is the sixth largest pharma company on that list, with annual revenue of US$51.8 billion in 2017.

Sinopharm is also the largest Chinese medical and healthcare group directly managed by the state-owned Assets Supervision and Administration Commission of the State Council (SASAC).

However, it is an early stage of this company’s development and if considering this stock for your portfolio you should take all public information into account and seek professional financial advice.

S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.